Drug Profile
Research programme: immunophilin ligands - Pfizer
Alternative Names: 3-NormeridamycinLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Macrolides
- Mechanism of Action Immunophilin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (IV)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 07 Aug 2009 Preclinical development is ongoing in USA